Skip Navigation LinksHome > January 28, 2009 - Volume 23 - Issue 3 > HIV-1 infection of human penile explant tissue and protectio...
AIDS:
doi: 10.1097/QAD.0b013e328321b778
Basic Science

HIV-1 infection of human penile explant tissue and protection by candidate microbicides

Fischetti, Luciaa; Barry, Sheila Mb; Hope, Thomas Jb; Shattock, Robin Ja

Free Access
Article Outline
Collapse Box

Author Information

aDepartment of Cellular and Molecular Medicine, Centre for infection, St George's University of London, Cranmer Terrace, Tooting, London, UK

bDepartment of Cell and Molecular Biology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois, USA.

Received 21 July, 2008

Revised 24 October, 2008

Accepted 4 November, 2008

Correspondence to Robin Shattock, St George's University of London, Cranmer Terrace, Tooting, London, SW170RE, UK. Tel: +44 181 725 5855; fax: +44 181 725 3487; e-mail: shattock@sgul.ac.uk

Collapse Box

Abstract

Objective: Factors governing events between exposure of male genital mucosa surfaces and the establishment of infection are poorly understood. Furthermore, little is known about the safety and efficacy of microbicides on male genital mucosa.

Design: Here we present a novel penile tissue explant model to characterize the mechanisms of HIV-1 infection of male genital tissue and evaluate candidate microbicides.

Methods: Mucosal explant culture conditions were determined for glans, urethra and foreskin obtained from gender reassignment and circumcision. Density and distribution of CD4+ and CD1a+ cells were visualized by microscopy. In vitro HIV-1 infection was determined by measuring p24 release, whereas microbicide biocompatibility and efficacy were assessed by measurement of tissue viability, cytokine expression and p24 production.

Results: Cultured glans and foreskin showed comparable epithelial thickness but some differences in CD4+ and CD1a+ cell density. All tissue sites examined (foreskin, glans, meatus, urethra) were equally susceptible to R5 HIV-1 infection, which was productively disseminated by migratory cells emigrating from tissue. In contrast, X4 HIV-1 failed to infect mucosal tissue and dissemination by migratory cells was less efficient. The three candidate microbicides poly(methyl 2-propionamidoacrylate), PRO 2000 and Cyanovirin-N, showed good tissue compatibility and efficient prevention of HIV-1 infection, causing only minor changes in tissue cytokine profile.

Conclusion: The described model provides a useful model to study the determinants of HIV-1 infection of male genital tissue and is likely to be an important tool for the future development of microbicide candidates and concepts.

Back to Top | Article Outline

Introduction

Thirty-three million people are living with HIV, half of them adult men [1]. Differences in the efficiency of male-to-female HIV transmission versus female-to-male are controversial [2–8] and may depend on several factors thought to influence the risk of female-to-male transmission [6,7,9], including circumcision [7,10–12]. Recent prophylactic trials demonstrate that circumcision could provide more than 50% protection against HIV infection [13–15], but provides no protection to female partners of HIV-positive men [16,17]. Explaining the association between circumcision and reduced HIV acquisition may provide important insight into the mechanism of transmission and development of intervention strategies. Previous reports suggest that a higher density and a more superficial presence of Langerhans cells together with reduced keratinization of the inner layer of foreskin, might increase HIV acquisition in uncircumcised men [18–21]. However, determinants of HIV infection in men are not fully understood and their characterization may aid microbicide development. Current microbicides have been designed to prevent female acquisition [22,23], assuming bi-directional protection [24]; however, no studies have tested the efficacy of microbicides against penile infection and their potential role in protecting men from insertive vaginal or rectal intercourse.

Using male genital tissue as an ex-vivo model of HIV-1 transmission, we evaluate the frequency of HIV target cells in foreskin, glans and urethra and their differential susceptibility to infection. Furthermore, we evaluate candidate microbicides for safety and efficacy against HIV transmission.

Back to Top | Article Outline

Patients and methods

Patients and tissue

Penile tissue was obtained following gender reassignment at Charing Cross Hospital, London, UK. All participants had ceased hormonal therapy a minimum of 6 weeks prior to surgery. Foreskin tissue was obtained following elective circumcision at St George's University of London, UK. All tissue was collected with written consent according to Local Research committee (LRC) guidelines. Penis and foreskin were cut into 2–3 mm3 explants comprising both epithelium and stroma. Tissue explants were cultured in RPMI 1640 medium supplemented with glutamax, 10% fetal calf serum (FCS), penicillin and streptomycin.

Back to Top | Article Outline
Measurement of tissue viability

Tissue explants were cultured for 10 days, with half medium replacement every 2–3 days. Tissue viability was measured by dimethyl thiazolyl diphenyl tetrazolium salt (MTT) dye reduction as previously described [25].

Back to Top | Article Outline
Immunohistochemistry

Tissue blocks were embedded in optimal cutting temperature compound (OCT), sectioned (12 μm) and stained. Langerhans cells were identified by CD1a ortho kung t6 [(OKT 6) hybridoma (American Type Culture Collection (ATCC)], CD4+ cells by anti-CD4 (clone Q4120, catalogue C1805; Sigma, St Louis, Missouri, USA). Donkey antimouse secondary antibodies were conjugated to Cy3, Cy5, Rhodamine Red-X conjugated (catalogue 715-295-150; Jackson Immunolabs, West Grove, Pennsylvania, USA) and Oregon Green (catalogue 06380; Molecular Probes, Eugene, Oregon, USA). Zenon Alexa Fluor 647 (catalogue Z25008; Molecular Probes) was utilized for antibody illumination. Epithelium was stained with wheat germ agglutinin (WGA) conjugated with Alexa fluor 594 (catalogue W11262; Molecular Probes).

Back to Top | Article Outline
Imaging of tissue slices

Images were collected on a DeltaVision RT system using a 40× oil objective, an Olympus IX71 microscope, and analysed using deconvolution microscopy software. Thirty z-sections, 0.5 μm apart, were collected per image field. All measurements were obtained through the ‘Measure Distances’ tool, using a standard two-point method.

Back to Top | Article Outline
Determination of microbicides cytotoxicity

Compounds used in this study were Cyanovirin-N (Biosyn Inc.; Huntingdon Valley, Pennsylvania, USA), PRO 2000 (Indevus Pharmaceutical, Lexington, Massachusetts, USA) and poly(methyl 2-propionamidoacrylate) (PMPA) (Gilead Sciences, Foster City, California, USA). Cyanovirin-N was provided unformulated, whereas PRO 2000 and PMPA were gel-formulated compounds. Placebo formulations containing the same excipients as the active product were also provided. All compounds were diluted into culture media. Potential toxicity of microbicides was measured as previously described [25].

Back to Top | Article Outline
Cells and viral cultures

PM1 cells (AIDS reagent project, NIBSC, Potters Bar, Hertfordshire, UK) were cultured in RPMI 1640 medium supplemented with glutamax, 10% FCS, penicillin and streptomycin. HIV-1BaL and HIV-1LaV were grown on peripheral blood mononuclear cells (PBMCs) as previously described [26] and the TCID50 determined.

Back to Top | Article Outline
HIV infection of human male genital tract tissue explants and dissemination by migratory cells

Tissue explants were exposed to HIVBaL or HIVLaV (104 TCID50/explant) for 2 h. Aldithriol-2 (10 mmol/l)-treated virus and medium only were used as negative controls. After washing with phosphate-buffered saline (PBS), explants were resuspended in medium ± phytohaemagglutinin (PHA; 10 μg/ml) overnight. The day after, tissue explants were removed and cultured ± PHA for 3 days, replaced by IL-2 (100 IU/ml) for the following 8 days. Migratory cells present in overnight culture plates were washed with PBS and cocultured with PM1 (40.000 cells/well) for 7 days. Culture supernatants were harvested every 2–3 days and assessed for p24 antigen level (HIV-1 p24 Antigen EIA, catalog # 626391, Beckman Coulter, High Wycombe, UK). Statistical analysis was performed using two-tailed t-test.

Back to Top | Article Outline
Screening of candidate microbicides

Tissue explants were treated with medium or compound just prior to exposure to HIV-1BaL (104 TCID50) for 2 h in presence of the compound. The samples were then washed with PBS and cultured in the absence of compound. The day after, migratory cells were separated from tissue as described above. Cultures were assessed for viral replication by p24 enzyme-linked immunosorbent assay (ELISA) as described.

Back to Top | Article Outline
Cytokine quantification

Tissue samples were cultured with or without compound for 2 h, washed with PBS and cultured in medium overnight. Supernatant was then collected and 23 cytokines quantified by in house multiplex bead immunoassay as described [27].

Back to Top | Article Outline

Results

Establishment of optimal culture conditions

Human male genital explant cultures were established by adapting previous methods developed for culture of cervicovaginal tissue [26]. Viability of explants in culture was assessed (data not shown). Glans, meatus and urethra maintained high viability for up to 7 days (average viability: 76.5–97.8%), with a slight decline by day 10 (62.7–76.7%). Inner and outer foreskin demonstrated shorter viability (75% at day 3 but 38% by day 7).

Back to Top | Article Outline
HIV target cell distribution

Genitourinary tissue was sectioned and stained with fluorescent antibodies to identify Langerhans cells and CD4+ cells following 0, 3 or 7 days in culture (Fig. 1a, b). Fluorescent WGA was used to reveal tissue structure and integrity.

Fig. 1
Fig. 1
Image Tools

For each target cell identified, we measured epithelial thickness, distance of the cell body to tissue surface and distance of the closest Langerhans cell projection to tissue surface (Fig. 1c). Epithelial thickness was determined by measuring the distance between the basement membrane and tissue surface, crossing through each cell body. Following 7 days in culture, specimens of inner foreskin were severely fragmented and lacked semblance of integrity. We, therefore, focused on differences in tissue from the initiation to 3 days in culture.

Overall, average epithelial thickness for each tissue type remained similar throughout the 3-day culture period (Fig. 2a), although inner foreskin decreased (100.4–92.4 μm) and glans epithelium increased in thickness (95.8–106.9 μm) after 3 days.

Fig. 2
Fig. 2
Image Tools

Similarly, the average distance of Langerhans cell bodies to tissue surface decreased in both inner (73.4–66.2 μm) and outer foreskin (71.6–61.3 μm), and increased in glans (57.3–66.7 μm) epithelium after 3 days in culture (Fig. 2b). Upon examination, we found no change in Langerhans cell projection distance to tissue surface over time for inner foreskin (Fig. 2c). However, Langerhans cell projections appeared to move closer to the tissue surface in outer foreskin (59.5–47.7 μm) and farther in glans (41.4–54.8 μm). These changes most likely reflect an increase in epithelial thickness observed with time.

Next we enumerated the number of Langerhans cells observed in each image. Although no difference in Langerhans cell number was observed in inner or outer foreskin samples after 3 days (Fig. 2d), for glans tissue we observed that the value decreased from 0.033 to 0.017 Langerhans cells/100 μm2 after 3 days. In addition, a significantly higher number of Langerhans cells were observed in glans compared with inner and outer foreskin, and in inner compared with outer foreskin, with an average of 0.023 and 0.017 Langerhans cells/100 μm2 in inner and outer foreskin, respectively. These values decreased to 0.02 and 0.016 Langerhans cells/100 μm2 by day 3.

The majority of CD4+ cells observed in the tissue specimens typically reside below the basement membrane in mucosal tissue, but may infiltrate surface epithelium under inflammatory conditions [28], whereas CD4+ Langerhans cells exclusively reside in the epithelium. No change was observed for CD4+ cell number for inner foreskin over 3 days in culture, but we detected a slight increase in outer foreskin, from 0.01 to 0.016 cells/100 μm2 (Fig. 2e). In contrast, significantly fewer CD4+ cells were found in glans following 3 days in culture. Here, we observed 0.037 CD4+ cells/100 μm2 imaged in glans tissue at the initiation of culture, decreasing to 0.013 cells/100 μm2 by day 3.

When the density of CD4+ cells was compared between tissue sites, glans tissue was found to contain the most CD4+ cells/100 μm2 at the initiation of the culture (Fig. 2e), whereas inner foreskin had 0.026 cells/100 μm2 or 2.6 times more than outer foreskin. By 3 days in culture, the only difference still detected was between inner foreskin and glans, with inner foreskin containing 1.6 times more CD4+ cells/100 μm2.

This trend continued for CD4+ cells observed within surface epithelium (Fig. 2f). Whereas no significant differences were observed in the number of CD4+ cells/100 μm2 of surface epithelium for either inner or outer foreskin, glans tissue exhibited a 2.7-fold decrease, from 0.0097 to 0.0037 after 3 days. In addition, glans showed significantly greater numbers of CD4+ cells in the epithelium compared with both inner (0.0019 CD4+ cells/100 μm2) and outer foreskin (0.0009 CD4+ cells/100 μm2) at the initiation of culture.

Despite these differences in cell number, the average distance of epithelial CD4+ cells to tissue surface remained unchanged in all tissue types throughout the culture period (Fig. 2g).

Back to Top | Article Outline
HIV infection of male genital tissue

Ex-vivo susceptibility to HIV-1 infection and relative efficiency of HIV dissemination by migratory cells were determined by exposing glans, urethra and foreskin to either HIV-1BaL (R5 isolate) or HIV-1LAV (X4 isolate). HIV-1BaL productively infected all tissue sites investigated (Fig. 3a), but no infection was detected with HIV-1LAV. Cellular emigrants from all tissue sites (±PHA) were able to disseminate HIV (BaL and LAV), but the level of HIV-1LAV p24 in culture supernatant was generally lower compared with HIV-1BaL (Fig. 3b,c). No significant differences in the level of HIV-1 infection either between different tissue sites or between activated versus nonactivated tissue and migratory cells were detected.

Fig. 3
Fig. 3
Image Tools
Back to Top | Article Outline
Cytokine release profile of male genital tissue explants

As cytokines can significantly modulate tissue susceptibility to HIV infection, the pattern of cytokine release from glans and foreskin after 24 h in culture was analysed (Fig. 4). IL-1-α, IL-4, IL-12, IL-15, tumour necrosis factor-α (TNF-α) and transforming growth factor-β (TGF-β) were all below or at the limit of detection for all three tissue sites. Among the cytokines produced at moderate levels, interferon-β (IFN-β), IFN-γ, monokine induced by γ-interferon (MIG), stromal cell derived factor 1-β (SDF-1-β), granulocyte-macrophage colony-stimulating factor (GM-CSF) and monocyte chemotactic protein (MCP-2) levels were significantly higher for both inner and outer foreskin compared with glans (P < 0.05), whereas IL-2 levels were only higher for outer foreskin compared with glans (P = 0.035). The same was observed for IL-6, IL-8, macrophage inflammatory protein (MIP-1-β), MCP-1 and interferon-γ-induced protein (IP-10) (P < 0.05) released at higher concentrations, whereas MIP-1-α and G-CSF were only released at significantly higher levels by inner foreskin (P < 0.01) when compared with glans. Inner and outer foreskin had a comparable pattern of cytokine release, with the exception of G-CSF, in which secretion by inner foreskin was significantly higher than outer foreskin (P = 0.006). Overall, both inner and outer foreskin demonstrated a significantly higher level of production of most secreted cytokines when compared with glans.

Fig. 4
Fig. 4
Image Tools
Back to Top | Article Outline
Evaluation of microbicide safety and efficacy

PRO 2000, PMPA and Cyanovirin-N were tested for their ability to inhibit HIV-1BaL infection and dissemination (Fig. 5). PMPA and PRO 2000 gel placebo demonstrated no activity against HIV infection (data not shown). No toxicity was detected at the highest concentrations tested for any of the compounds (data not shown).

Fig. 5
Fig. 5
Image Tools

PMPA at 1 mg/ml (10-fold dilution of the original 1% stock gel) inhibited HIV infection of glans by 90%, and completely inhibited dissemination by migratory cells (Fig. 5a). PRO 2000 at 100 μg/ml (400-fold dilution of the original 4% stock gel) inhibited infection by 99.4%, and dissemination of infection was totally suppressed (Fig. 5b). Cyanovirin-N at 11 μg/ml prevented HIV replication in tissue (95%) and propagation of the virus by migratory cells (99%; Fig. 5c). Similar results were obtained when tested on foreskin (data not shown).

PMPA, PRO 2000 and Cyanovirin-N had little effect on the 23 cytokines tested and none affected cytokine release by outer foreskin. However, Cyanovirin-N at 11 μg/ml increased production of SDF-1-β (2.8-fold) and MIP-1-β (2.9-fold) in glans, and IL-2 (two-fold), IFN-β (2.4-fold), IFN-γ (1.6-fold), MIG (21.2-fold), GM-CSF (1.4-fold), IP-10 (2.7-fold) and MCP-2 (1.8-fold) in inner foreskin (P < 0.05). PRO 2000 at 100 μg/ml did not induce any modification in cytokine release by both inner and outer foreskin, but reduced the production of SDF-1-β (2.3-fold; P < 0.01), MIP-1-β (six-fold), IP-10 (3.1-fold) and MCP-2 (2.7-fold; P < 0.05) in glans. PMPA 1 mg/ml did not exert any significant variation in cytokine release for all tissue sites tested, with the only exception of inner foreskin, where SDF-1-β release increased two-fold (P < 0.05).

Back to Top | Article Outline

Discussion

All male genital tissue sites examined adapted well to explant culture, with the exception of foreskin, that lost tissue integrity after 3 days, most likely reflecting that foreskin epithelium is supported by a thinner layer of stroma compared with the other tissue sites. Interestingly, foreskin explants released higher levels of cytokines compared with glans, suggesting a higher level of immune activation. At the initiation of culture, the average number of Langerhans cells and CD4+ cells was greatest for glans > inner foreskin > outer foreskin, in agreement with a previous report [19] comparing inner and outer foreskin. However, another study reported a higher density of CD4+ cells and Langerhans cells in outer foreskin > inner foreskin > glans [18]. These discrepancies might reflect that in the latter study, tissue was obtained postmortem or that foreskin and glans tissue in this study were not taken from the same donors.

The distance of dendritic projections emanating from Langerhans cell bodies was closest to the epithelial surface for glan > inner = outer foreskin. These observations also differ to those of McCoombe and Short [18], in which Langerhans cell bodies and projections were particularly superficial in inner foreskin. In agreement with both previous studies [18,19], CD4+ cells in all tissue sites were predominantly distributed within the stroma underlying the epithelium. Significant changes in cell number and dendritic projections were observed in culture. The most pronounced being the decrease in CD4+ and CD1a+ cells in glans by day 3, suggesting a considerable migration of both CD4+ cells and Langerhans cells, out of the tissue. In contrast, the number of Langerhans cells and CD4+ cells in the epithelium of both inner and outer foreskin were fairly stable.

All genital tissue sites examined were susceptible to R5 HIV-1BaL infection, independent of immune activation. In contrast, no infection was observed with X4 HIV-1LAV. These data confirm a previous study of human foreskin [19] and reflect the predominant CCR5 expression in foreskin and cervical tissue [19,29,30]. However, this is not the case for penile glans and urethral meatus, reported to have equal levels of CCR5 and CXCR4 expression [18,19]. Interestingly, migratory cells from all male tissue sites also preferentially transmitted HIV-1BaL over HIV-1LAV, in agreement with previous observations that in vitro derived Langerhans cells and dendritic cells preferentially transmit R5 virus [31–38].

To investigate the potential role of male genital explants as a model for microbicide development, we selected three microbicide candidates: PRO 2000, which is in phase III efficacy trials [39–41]; PMPA gel (tenofovir), which is in phase II trials ([42], www.microbicides.org); and Cyanovirin-N, which is in preclinical development [43–46]. PRO 2000 at 100 μg/ml (1/50 of the vaginal gel) provided nearly complete suppression of viral infection and dissemination in penile tissue, with no toxicity and little modulation of cytokine expression. These data are in agreement with previous studies of cervical and rectal tissue [25,26,47] and with a clinical study demonstrating safety for 4% gel applied daily on the penis [48]. PMPA at 1 mg/ml (1/10 of the vaginal gel) demonstrated potent activity against R5 HIV-1BaL infection of glans tissue and dissemination of virus. However, it was less active than a previous study using colorectal explants [47]. PMPA demonstrated no toxicity for penile tissue and little modulation of cytokine expression, in agreement with human studies demonstrating good tolerability of PMPA gel 1% applied vaginally [49]. Cyanovirin-N conferred 95% protection against HIV-1BaL at 11 μg/ml similar to that seen in cervical explants [45] and at a dose 1/500 of that shown to be protective in macaques [45,46]. The ability to block HIV-1 transfer by migratory cells was in agreement with the ability of Cyanovirin-N to impair dendritic cell-specific intercellular adhesion molecule-3-grabbing non-integrin (DC-SIGN)-mediated HIV-1 transmission in vitro [50]. Although Cyanovirin-N was not toxic for male genital tissue explants, we observed a degree of cytokine disregulation following 2 h exposure to Cyanovirin-N, in line with previous reports [51].

In summary, this study describes an ex-vivo model to study the vulnerability of male genital mucosa to HIV infection. Although we observed some differences in the frequency of target cells (CD4+ and Langerhans cells) between tissue sites, all sites examined were susceptible to HIV-1 (R5) infection. We found no evidence to support enhanced susceptibility of inner foreskin relative to glans and outer foreskin. Nevertheless, circumcision would remove two out of three of the exposed surface areas of the penis, reducing the chance of virus coming in contact with susceptible target cells. The susceptibility to infection and the observed inhibition by three different microbicides, two of which are already in clinical trials, offer new perspectives for the development of compounds able to protect male genital tissue from HIV transmission.

Back to Top | Article Outline

Acknowledgements

We are most grateful to Mr James Bellringer, Consultant Urologist and Gender Surgeon of Charing Cross Hospital, London, for provision of penile tissue samples and to St George's Hospital, London for providing the foreskin tissue, as well as the many tissue donors who have contributed to this work. We also would like to thank Ms Naomi Louise Armanasco for coordinating the tissue specimen collection.

R.J.S. and L.F. designed the experiments; L.F. performed the cellular and explant experiments; S.M.B. and T.J.H. performed all the immunohistochemistry and imaging analysis; R.J.S., L.F. and T.J.H. wrote the article.

The present work was funded by the National Institutes for Health Grant R21 HDO 48391-01. LF is supported by Grant Number F30DA023367 from the National Institute On Drug Abuse. We also acknowledge the generous grant from the Fondation Dormeur that facilitated purchase of equipment used in this project.

Back to Top | Article Outline

References

1. WHO. 2007 AIDS epidemic update; 2007.

2. European Study Group on Heterosexual Transmission of HIV. Comparison of female to male and male to female transmission of HIV in 563 stable couples. BMJ 1992; 304:809–813.

3. Hugonnet S, Mosha F, Todd J, Mugeye K, Klokke A, Ndeki L, et al. Incidence of HIV infection in stable sexual partnerships: a retrospective cohort study of 1802 couples in Mwanza Region, Tanzania. J Acquir Immune Defic Syndr 2002; 30:73–80.

4. Nicolosi A, Correa Leite ML, Musicco M, Arici C, Gavazzeni G, Lazzarin A. The efficiency of male-to-female and female-to-male sexual transmission of the human immunodeficiency virus: a study of 730 stable couples. Italian Study Group on HIV Heterosexual Transmission. Epidemiology 1994; 5:570–575.

5. Padian NS, Shiboski SC, Jewell NP. Female-to-male transmission of human immunodeficiency virus. JAMA 1991; 266:1664–1667.

6. Gray RH, Wawer MJ, Brookmeyer R, Sewankambo NK, Serwadda D, Wabwire-Mangen F, et al. Probability of HIV-1 transmission per coital act in monogamous, heterosexual, HIV-1-discordant couples in Rakai, Uganda. Lancet 2001; 357:1149–1153.

7. Quinn TC, Wawer MJ, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med 2000; 342:921–929.

8. Serwadda D, Gray RH, Wawer MJ, Stallings RY, Sewankambo NK, Konde-Lule JK, et al. The social dynamics of HIV transmission as reflected through discordant couples in rural Uganda. AIDS 1995; 9:745–750.

9. Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Li X, Laeyendecker O, et al. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. J Infect Dis 2005; 191:1403–1409.

10. Gray RH, Kiwanuka N, Quinn TC, Sewankambo NK, Serwadda D, Mangen FW, et al. Male circumcision and HIV acquisition and transmission: cohort studies in Rakai, Uganda. Rakai Project Team. AIDS 2000; 14:2371–2381.

11. Siegfried N, Muller M, Deeks J, Volmink J, Egger M, Low N, et al. HIV and male circumcision – a systematic review with assessment of the quality of studies. Lancet Infect Dis 2005; 5:165–173.

12. Weiss HA, Quigley MA, Hayes RJ. Male circumcision and risk of HIV infection in sub-Saharan Africa: a systematic review and meta-analysis. AIDS 2000; 14:2361–2370.

13. Auvert B, Taljaard D, Lagarde E, Sobngwi-Tambekou J, Sitta R, Puren A. Randomized, controlled intervention trial of male circumcision for reduction of HIV infection risk: the ANRS 1265 Trial. PLoS Med 2005; 2:e298.

14. Bailey RC, Moses S, Parker CB, Agot K, Maclean I, Krieger JN, et al. Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial. Lancet 2007; 369:643–656.

15. Gray RH, Kigozi G, Serwadda D, Makumbi F, Watya S, Nalugoda F, et al. Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial. Lancet 2007; 369:657–666.

16. Wawer MJ, Kigozi G, Serwadda D, Makumbi F, Nalugoda F, Watya S, et al. Trial of male circumcision in HIV+ men, Rakai, Uganda: effects in HIV+ men and in women partners. 15th Conference on Retroviruses and Opportunistic Infections; 2008; Boston, MA, United States.

17. Turner AN, Morrison CS, Padian NS, Kaufman JS, Salata RA, Chipato T, et al. Men's circumcision status and women's risk of HIV acquisition in Zimbabwe and Uganda. AIDS 2007; 21:1779–1789.

18. McCoombe SG, Short RV. Potential HIV-1 target cells in the human penis. AIDS 2006; 20:1491–1495.

19. Patterson BK, Landay A, Siegel JN, Flener Z, Pessis D, Chaviano A, Bailey RC. Susceptibility to human immunodeficiency virus-1 infection of human foreskin and cervical tissue grown in explant culture. Am J Pathol 2002; 161:867–873.

20. Donoval BA, Landay AL, Moses S, Agot K, Ndinya-Achola JO, Nyagaya EA, et al. HIV-1 target cells in foreskins of African men with varying histories of sexually transmitted infections. Am J Clin Pathol 2006; 125:386–391.

21. Hussain LA, Lehner T. Comparative investigation of Langerhans' cells and potential receptors for HIV in oral, genitourinary and rectal epithelia. Immunology 1995; 85:475–484.

22. Lederman MM, Offord RE, Hartley O. Microbicides and other topical strategies to prevent vaginal transmission of HIV. Nat Rev Immunol 2006; 6:371–382.

23. Shattock RJ, Moore JP. Inhibiting sexual transmission of HIV-1 infection. Nat Rev Microbiol 2003; 1:25–34.

24. Watts C, Kumaranayake L, Vickerman P, Terris-Prestholt F. The public health benefits of microbicides in lower-income countries. Public Health Working Group. New York: Rockefeller Foundation; 2002.

25. Fletcher PS, Wallace GS, Mesquita PM, Shattock RJ. Candidate polyanion microbicides inhibit HIV-1 infection and dissemination pathways in human cervical explants. Retrovirology 2006; 3:46.

26. Greenhead P, Hayes P, Watts PS, Laing KG, Griffin GE, Shattock RJ. Parameters of human immunodeficiency virus infection of human cervical tissue and inhibition by vaginal virucides. J Virol 2000; 74:5577–5586.

27. Biancotto A, Grivel JC, Iglehart SJ, Vanpouille C, Lisco A, Sieg SF, et al. Abnormal activation and cytokine spectra in lymph nodes of people chronically infected with HIV-1. Blood 2007; 109:4272–4279.

28. Galvin SR, Cohen MS. The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol 2004; 2:33–42.

29. Patterson BK, Landay A, Andersson J, Brown C, Behbahani H, Jiyamapa D, et al. Repertoire of chemokine receptor expression in the female genital tract: implications for human immunodeficiency virus transmission. Am J Pathol 1998; 153:481–490.

30. Yeaman GR, Asin S, Weldon S, Demian DJ, Collins JE, Gonzalez JL, et al. Chemokine receptor expression in the human ectocervix: implications for infection by the human immunodeficiency virus-type I. Immunology 2004; 113:524–533.

31. Zaitseva M, Blauvelt A, Lee S, Lapham CK, Klaus-Kovtun V, Mostowski H, et al. Expression and function of CCR5 and CXCR4 on human Langerhans cells and macrophages: implications for HIV primary infection. Nat Med 1997; 3:1369–1375.

32. Kawamura T, Cohen SS, Borris DL, Aquilino EA, Glushakova S, Margolis LB, et al. Candidate microbicides block HIV-1 infection of human immature Langerhans cells within epithelial tissue explants. J Exp Med 2000; 192:1491–1500.

33. David SA, Smith MS, Lopez GJ, Adany I, Mukherjee S, Buch S, et al. Selective transmission of R5-tropic HIV type 1 from dendritic cells to resting CD4+ T cells. AIDS Res Hum Retroviruses 2001; 17:59–68.

34. Granelli-Piperno A, Delgado E, Finkel V, Paxton W, Steinman RM. Immature dendritic cells selectively replicate macrophagetropic (M-tropic) human immunodeficiency virus type 1, while mature cells efficiently transmit both M- and T-tropic virus to T cells. J Virol 1998; 72:2733–2737.

35. Kawamura T, Gulden FO, Sugaya M, McNamara DT, Borris DL, Lederman MM, et al. R5 HIV productively infects Langerhans cells, and infection levels are regulated by compound CCR5 polymorphisms. Proc Natl Acad Sci U S A 2003; 100:8401–8406.

36. Reece JC, Handley AJ, Anstee EJ, Morrison WA, Crowe SM, Cameron PU. HIV-1 selection by epidermal dendritic cells during transmission across human skin. J Exp Med 1998; 187:1623–1631.

37. Fahrbach KM, Barry SM, Ayehunie S, Lamore S, Klausner M, Hope TJ. Activated CD34-derived Langerhans cells mediate transinfection with human immunodeficiency virus. J Virol 2007; 81:6858–6868.

38. Turville SG, Santos JJ, Frank I, Cameron PU, Wilkinson J, Miranda-Saksena M, et al. Immunodeficiency virus uptake, turnover, and 2-phase transfer in human dendritic cells. Blood 2004; 103:2170–2179.

39. Moulard M, Lortat-Jacob H, Mondor I, Roca G, Wyatt R, Sodroski J, et al. Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. J Virol 2000; 74:1948–1960.

40. Neurath AR, Strick N, Li YY. Anti-HIV-1 activity of anionic polymers: a comparative study of candidate microbicides. BMC Infect Dis 2002; 2:27.

41. Fletcher PS, Shattock RJ. PRO-2000, an antimicrobial gel for the potential prevention of HIV infection. Curr Opin Investig Drugs 2008; 9:189–200.

42. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004; 292:191–201.

43. Botos I, O'Keefe BR, Shenoy SR, Cartner LK, Ratner DM, Seeberger PH, et al. Structures of the complexes of a potent anti-HIV protein cyanovirin-N and high mannose oligosaccharides. J Biol Chem 2002; 277:34336–34342.

44. Boyd MR, Gustafson KR, McMahon JB, Shoemaker RH, O'Keefe BR, Mori T, et al. Discovery of cyanovirin-N, a novel human immunodeficiency virus-inactivating protein that binds viral surface envelope glycoprotein gp120: potential applications to microbicide development. Antimicrob Agents Chemother 1997; 41:1521–1530.

45. Tsai CC, Emau P, Jiang Y, Agy MB, Shattock RJ, Schmidt A, et al. Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. AIDS Res Hum Retroviruses 2004; 20:11–18.

46. Tsai CC, Emau P, Jiang Y, Tian B, Morton WR, Gustafson KR, Boyd MR. Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SHIV89.6P in macaques. AIDS Res Hum Retroviruses 2003; 19:535–541.

47. Fletcher PS, Elliott J, Grivel JC, Margolis L, Anton P, McGowan I, Shattock RJ. Ex vivo culture of human colorectal tissue for the evaluation of candidate microbicides. AIDS 2006; 20:1237–1245.

48. Tabet SR, Callahan MM, Mauck CK, Gai F, Coletti AS, Profy AT, et al. Safety and acceptability of penile application of 2 candidate topical microbicides: BufferGel and PRO 2000 Gel: 3 randomized trials in healthy low-risk men and HIV-positive men. J Acquir Immune Defic Syndr 2003; 33:476–483.

49. Mayer KH, Maslankowski LA, Gai F, El-Sadr WM, Justman J, Kwiecien A, et al. Safety and tolerability of tenofovir vaginal gel in abstinent and sexually active HIV-infected and uninfected women. AIDS 2006; 20:543–551.

50. Balzarini J, Van Herrewege Y, Vermeire K, Vanham G, Schols D. Carbohydrate-binding agents efficiently prevent dendritic cell-specific intercellular adhesion molecule-3-grabbing nonintegrin (DC-SIGN)-directed HIV-1 transmission to T lymphocytes. Mol Pharmacol 2007; 71:3–11.

51. Balzarini J, Van Laethem K, Peumans WJ, Van Damme EJ, Bolmstedt A, Gago F, Schols D. Mutational pathways, resistance profile, and side effects of cyanovirin relative to human immunodeficiency virus type 1 strains with N-glycan deletions in their gp120 envelopes. J Virol 2006; 80:8411–8421.

Cited By:

This article has been cited 15 time(s).

Mucosal Immunology
An African perspective on mucosal immunity and HIV-1
Pala, P; Gomez-Roman, VR; Gilmour, J; Kaleebu, P
Mucosal Immunology, 2(4): 300-314.
10.1038/mi.2009.23
CrossRef
Journal of Investigative Dermatology
Vaccines and Microbicides Preventing HIV-1, HSV-2, and HPV Mucosal Transmission
Nikolic, DS; Piguet, V
Journal of Investigative Dermatology, 130(2): 352-361.
10.1038/jid.2009.227
CrossRef
Mucosal Immunology
Enhanced cellular responses and environmental sampling within inner foreskin explants: implications for the foreskin's role in HIV transmission
Fahrbach, KM; Barry, SM; Anderson, MR; Hope, TJ
Mucosal Immunology, 3(4): 410-418.
10.1038/mi.2010.18
CrossRef
Applied Microbiology and Biotechnology
The antiviral protein cyanovirin-N: the current state of its production and applications
Xiong, S; Fan, J; Kitazato, K
Applied Microbiology and Biotechnology, 86(3): 805-812.
10.1007/s00253-010-2470-1
CrossRef
Archives of Pediatrics & Adolescent Medicine
Male Circumcision for the Prevention of Acquisition and Transmission of Sexually Transmitted Infections The Case for Neonatal Circumcision
Tobian, AAR; Gray, RH; Quinn, TC
Archives of Pediatrics & Adolescent Medicine, 164(1): 78-84.

American Journal of Pathology
Abundant Expression of HIV Target Cells and C-Type Lectin Receptors in the Foreskin Tissue of Young Kenyan Men
Hirbod, T; Bailey, RC; Agot, K; Moses, S; Ndinya-Achola, J; Murugu, R; Andersson, J; Nilsson, J; Broliden, K
American Journal of Pathology, 176(6): 2798-2805.
10.2353/ajpath.2010.090926
CrossRef
Journal of Virology
CCR5-and CXCR4-Tropic Subtype C Human Immunodeficiency Virus Type 1 Isolates Have a Lower Level of Pathogenic Fitness than Other Dominant Group M Subtypes: Implications for the Epidemic
Abraha, A; Nankya, IL; Gibson, R; Demers, K; Tebit, DM; Johnston, E; Katzenstein, D; Siddiqui, A; Herrera, C; Fischetti, L; Shattock, RJ; Arts, EJ
Journal of Virology, 83(): 5592-5605.
10.1128/JVI.02051-08
CrossRef
Antiviral Research
The candidate sulfonated microbicide, PRO 2000, has potential multiple mechanisms of action against HIV-1
Huskens, D; Vermeire, K; Profy, AT; Schols, D
Antiviral Research, 84(1): 38-47.
10.1016/j.antiviral.2009.07.013
CrossRef
Current Hiv Research
Small Ruminant Lentiviruses and Human Immunodeficiency Virus: Cousins that Take a Long View
Blacklaws, BA; Harkiss, GD
Current Hiv Research, 8(1): 26-52.

Applied Microbiology and Biotechnology
Soluble cytoplasmic expression, rapid purification, and characterization of cyanovirin-N as a His-SUMO fusion
Gao, XL; Chen, W; Guo, CW; Qian, CW; Liu, G; Ge, F; Huang, YD; Kitazato, K; Wang, YF; Xiong, S
Applied Microbiology and Biotechnology, 85(4): 1051-1060.
10.1007/s00253-009-2078-5
CrossRef
Cold Spring Harbor Perspectives in Medicine
HIV Transmission
Shaw, GM; Hunter, E
Cold Spring Harbor Perspectives in Medicine, 2(): -.
ARTN a006965
CrossRef
Mucosal Immunology
The adult penile urethra is a novel entry site for HIV-1 that preferentially targets resident urethral macrophages
Ganor, Y; Zhou, Z; Bodo, J; Tudor, D; Leibowitch, J; Mathez, D; Schmitt, A; Vacher-Lavenu, MC; Revol, M; Bomsel, M
Mucosal Immunology, 6(4): 776-786.
10.1038/mi.2012.116
CrossRef
Reviews in Medical Virology
Tissue dendritic cells as portals for HIV entry
Harman, AN; Kim, M; Nasr, N; Sandgren, KJ; Cameron, PU
Reviews in Medical Virology, 23(5): 319-333.
10.1002/rmv.1753
CrossRef
Biosocieties
Surveying risk subjects: Public health surveys as instruments of biomedicalization
Norton, AT
Biosocieties, 8(3): 265-288.
10.1057/biosoc.2013.20
CrossRef
Current Opinion in Infectious Diseases
Microbicides for HIV prevention: reality or hope?
McGowan, I
Current Opinion in Infectious Diseases, 23(1): 26-31.
10.1097/QCO.0b013e328334fe70
PDF (314) | CrossRef
Back to Top | Article Outline
Keywords:

foreskin; glans; HIV-1; microbicide; tissue explant

© 2009 Lippincott Williams & Wilkins, Inc.

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.